Jiangsu HengRui Medicine Co., Ltd. clinical trial pipeline
Data updated daily from ClinicalTrials.gov, last refresh 2026-11-19
What changed in the last 30 days
4 trials changed in the last 30 days: 0 stopped, 2 with notable changes, 2 with minor changes only.
- Notable: FH-006 Versus Investigator's Choice of Chemotherapy · Locally Advanced, Recurrent, or Metastatic Esophageal Squamous Cell Carcinoma Who Have Failed Prior PD-1/PD-L1 Inhibitor Combined With Platinum-Based Chemotherapy Recruitment opened
- Notable: HRS-7172 in Combination With Antitumor Therapy · Solid Tumors Recruitment opened
- Minor: HRS-8427 · Bacterial Pneumonia Trial completed
- Minor: HRS-6209 in Combination With Other Antitumor Therapies in Breast Cancer Patients or HRS-9813 as Monotherapy · Advanced Solid Tumors Trial arms changed: 9 → 13
- Stopped: terminated, suspended or withdrawn
- Notable: the plan changed
- Minor: routine updates
New trial filings, last 30 days
| First posted | Trial | Phase | Status |
|---|---|---|---|
| 2026-11-06 | NCT07920939 Efficacy and Safety of Once-Weekly SHR-3167 Compared With Once-Daily Insulin Glargine in… | Phase 3 | Not Yet Recruiting |
| 2026-11-03 | NCT07913061 A Study Comparing SHR-3167 With Insulin Degludec in Adults With Type 2 Diabetes Currently… | Phase 3 | Not Yet Recruiting |
| 2026-10-26 | NCT07894328 A Phase III Clinical Study of HRS-6209 Plus Letrozole as First-line Therapy in Patients… | Phase 3 | Not Yet Recruiting |
Active trials by phase
| Phase 1 | 20 | |
| Phase 1/2 | 20 | |
| Phase 2 | 21 | |
| Phase 2/3 | 1 | |
| Phase 3 | 30 | |
| Phase 4 | 1 |
Disease areas by active trials, top 10 of 22
Breast Cancer (12) · Prostate Cancer (12) · Diabetes (6) · Lung Cancer (6) · HER2-Positive Cancer (5) · Type 2 Diabetes (5) · Non-Small Cell Lung Cancer (NSCLC) (4) · Psoriasis (4) · Gastric Cancer (3) · Non-Hodgkin Lymphoma (3)
Get alerts when Jiangsu HengRui Medicine Co., Ltd.'s trials change
Status changes, date slips, and new filings: detected daily, delivered to your inbox.